FibroGen EBITDA 2013-2025 | FGEN

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

FibroGen ebitda from 2013 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

FibroGen ebitda from 2013 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Related Stocks
Company Name	Market Cap
Chugai Pharmaceutical (CHGCY)	$79.5B
Zoetis (ZTS)	$68B
Daiichi Sankyo, - (DSNKY)	$46.9B
Takeda Pharmaceutical (TAK)	$46.6B
BeOne Medicines - (ONC)	$32.5B
Sandoz Group AG (SDZNY)	$26.5B
Summit Therapeutics (SMMT)	$20.5B
Merck (MKKGY)	$17.3B
Shionogi (SGIOY)	$14.6B
United Therapeutics (UTHR)	$13.8B
Neurocrine Biosciences (NBIX)	$13B
Orion OYJ (ORINY)	$11.7B
IPSEN (IPSEY)	$11.1B
Stevanato Group S.p.A (STVN)	$8.5B
Corcept Therapeutics (CORT)	$7.2B
Grifols, S.A (GRFS)	$6.8B
Ionis Pharmaceuticals (IONS)	$6.7B
Madrigal Pharmaceuticals (MDGL)	$6.6B
Hikma Pharmaceuticals Plc (HKMPF)	$6.2B
Ono Pharmaceutical (OPHLF)	$5.2B
Soleno Therapeutics (SLNO)	$4.4B
Hypermarcas (HYPMY)	$3.1B
Crinetics Pharmaceuticals (CRNX)	$2.8B
NewAmsterdam Pharma (NAMS)	$2.6B
Catalyst Pharmaceuticals (CPRX)	$2.6B
Procaps Group, S.A (PROCF)	$2.5B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.5B
Centessa Pharmaceuticals (CNTA)	$2.1B
Ocular Therapeutix (OCUL)	$1.9B
BioCryst Pharmaceuticals (BCRX)	$1.8B